EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC 4.0

Inhaled anti-TSLP antibody fragment, ecleralimab, blocks responses to allergen in mild asthma

Gail M Gauvreau, Jens M Hohlfeld iD, J Mark FitzGerald, Louis-Philippe Boulet, Donald W Cockcroft, Beth E Davis, Stephanie Korn, Oliver Kornmann, Richard Leigh, Irvin Mayers, Henrik Watz, Sarah S Grant und 7 weitere

European Respiratory Journal · 2023-03 · 61 (3) · 2201193

DOI: 10.1183/13993003.01193-2022 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Respiratory Journal, online erschienen am 23.02.2023. Verfasst von Gail M Gauvreau und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, McMaster University, Hamilton, ON, Canada gauvreau@mcmaster.ca. Hauptthemen laut MEDLINE: Asthma, Hypersensitivity, Immediate. Die Arbeit wurde bisher 72-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AllerGen National Center of Excellence, Novartis Pharma AG, Basel, Switzerland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Thymic stromal lymphopoietin (TSLP) is a key upstream regulator driving allergic inflammatory responses. We evaluated the efficacy and safety of ecleralimab, a potent inhaled neutralising antibody fragment against human TSLP, using allergen inhalation challenge (AIC) in subjects with mild atopic asthma.

Methods

This was a 12-week, randomised, double-blind, placebo-controlled, parallel-design, multicentre allergen bronchoprovocation study conducted at 10 centres across Canada and Germany. Subjects aged 18–60 years with stable mild atopic asthma were randomised (1:1) to receive 4 mg once-daily inhaled ecleralimab or placebo. Primary end-points were the allergen-induced change in forced expiratory volume in 1 s (FEV 1 ) during the late asthmatic response (LAR) measured by area under the curve (AUC 3–7h ) and maximum percentage decrease (LAR%) on day 84, and the safety of ecleralimab. Allergen-induced early asthmatic response (EAR), sputum eosinophils and fractional exhaled nitric oxide ( F ENO ) were secondary and exploratory end-points.

Results

28 subjects were randomised to ecleralimab (n=15) or placebo (n=13). On day 84, ecleralimab significantly attenuated LAR AUC 3–7h by 64% (p=0.008), LAR% by 48% (p=0.029), and allergen-induced sputum eosinophils by 64% at 7 h (p=0.011) and by 52% at 24 h (p=0.047) post-challenge. Ecleralimab also numerically reduced EAR AUC 0–2h (p=0.097) and EAR% (p=0.105). F ENO levels were significantly reduced from baseline throughout the study (p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaHypersensitivity, ImmediateHumansAdministration, InhalationAllergensBronchial Provocation TestsCross-Over StudiesCytokinesDouble-Blind MethodForced Expiratory VolumeImmunoglobulin FragmentsSputumThymic Stromal LymphopoietinAdolescentYoung AdultAdultMiddle Aged

Substanzen

AllergensCytokinesImmunoglobulin FragmentsThymic Stromal Lymphopoietin

Autor:innen und Institutionen

  • Department of Medicine, McMaster University, Hamilton, ON, Canada gauvreau@mcmaster.ca.
  • These authors contributed equally to this work.
  • Fraunhofer Institute for Toxicology and Experimental Medicine and Hannover Medical School, Hannover, Germany.
  • Centre for Lung Health, University of British Columbia, Vancouver, BC, Canada.
  • Québec Heart and Lung Institute, Laval University, Québec, QC, Canada.
  • Division of Respirology, Critical Care and Sleep Medicine, Department of Medicine, University of Saskatchewan, Saskatoon, SK, Canada.

ORCID-Profile: Jens M Hohlfeld, Maciej Cabanski, Paul M O'Byrne

Förderung

  • AllerGen National Center of Excellence
  • Novartis Pharma AG, Basel, Switzerland

Zitieren

APA

Gauvreau, G. M., Hohlfeld, J. M., FitzGerald, J. M., Boulet, L. P., Cockcroft, D. W., Davis, B. E., Korn, S., Kornmann, O., Leigh, R., Mayers, I., Watz, H., Grant, S. S., Jain, M., Cabanski, M., Pertel, P. E., Jones, I., Lecot, J. R., Cao, H., & O'Byrne, P. M. (2023). Inhaled anti-TSLP antibody fragment, ecleralimab, blocks responses to allergen in mild asthma. European Respiratory Journal, 61(3), 2201193. https://doi.org/10.1183/13993003.01193-2022

Vancouver

Gauvreau GM, Hohlfeld JM, FitzGerald JM, Boulet LP, Cockcroft DW, Davis BE, et al. Inhaled anti-TSLP antibody fragment, ecleralimab, blocks responses to allergen in mild asthma. European Respiratory Journal. 2023;61(3):2201193. doi:10.1183/13993003.01193-2022

BibTeX
@article{Gauvreau2023,
  author = {Gauvreau, Gail M and Hohlfeld, Jens M and FitzGerald, J Mark and Boulet, Louis-Philippe and Cockcroft, Donald W and Davis, Beth E and Korn, Stephanie and Kornmann, Oliver and Leigh, Richard and Mayers, Irvin and Watz, Henrik and Grant, Sarah S and Jain, Monish and Cabanski, Maciej and Pertel, Peter E and Jones, Ieuan and Lecot, Jean R and Cao, Hui and O'Byrne, Paul M},
  title = {Inhaled anti-TSLP antibody fragment, ecleralimab, blocks responses to allergen in mild asthma},
  journal = {European Respiratory Journal},
  year = {2023},
  volume = {61},
  number = {3},
  pages = {2201193},
  doi = {10.1183/13993003.01193-2022}
}
Kostenlos starten →